Comparative Pharmacology
Head-to-head clinical analysis: UNASYN versus UNIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNASYN versus UNIPEN.
UNASYN vs UNIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
None Documented
None Documented
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic